Wan Yang Feng, Ph.D. has been appointed Director of Bioanalytic and Metabolism of Bridge Pharmaceutical's Preclinical Laboratory in Beijing.SAN FRANCISCO -- Bridge Pharmaceuticals announced today that Dr. Wan Yang Feng has been appointed Director of Bioanalytic and Metabolism in its Beijing subsidiary effective immediately. Dr. Feng's areas of responsibility will include analytic methods development and validation, metabolic profiling of new pharmaceutical drugs, drug-drug interactions, and adsorption and general pharmacology assessment. Prior to joining Bridge, Dr. Feng worked in Novartis Institutes for BioMedical Research (NIBR) (formerly Chiron) for more than five years. During his tenure at NIBR, he was responsible for drug metabolism, pharmacokinetics and bioanalytical chemistry. His work played critical roles in characterizing ADME/PK properties of antibacterial and cancerous drugs from hit-to-lead to IND filing, as well as early phase I and II clinical trials for several discovery and development projects. He was also a manager of Chiron's large mass spectrometry laboratory. "We are extremely pleased to have someone of Dr. Feng's caliber joining our scientific team in Beijing. His technical expertise and NIBR/Chiron experience reinforces our goal to provide fully FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. compliant preclinical studies in our US-level GLP See gateway location protocol. laboratory in Beijing," said Dr. Ada Kung Ph.D., DABT, EVP and CTO of Bridge. Dr. Feng has been widely recognized as an expert in mass spectrometry, bioanalytical chemistry and drug metabolism. He has been an author or co-author of over 40 publications including 11 invited review papers published in well-known journals such as Current Drug Discovery Technologies, Expert Opinion on Drug Discovery, and Current Drug Metabolism. Prior to NIBR, he worked in bioanalytical chemistry, pharmacokinetics, drug metabolism, enzymatic kinetics, mass spectrometry and gas phase ion chemistry Gas phase ion chemistry is a field of science encompassed dually within both Chemistry and Physics. It is the science that studies ions and molecules in the gas phase, most often enabled by some form of mass spectrometry. at Ohio State University Ohio State University, main campus at Columbus; land-grant and state supported; coeducational; chartered 1870, opened 1873 as Ohio Agricultural and Mechanical College, renamed 1878. There are also campuses at Lima, Mansfield, Marion, and Newark. , San Francisco State University • • [ and The Hebrew University of Jerusalem Hebrew University of Jerusalem Independent university in Jerusalem, Israel, founded in 1925. The foremost university in Israel, it attracts many Jewish students from abroad; Arab students also attend. . Currently, he is members of International Society for the Study Xenobiotics (ISSX) and American Society for Mass Spectrometry The American Society for Mass Spectrometry is a professional association based in the United States that supports the scientific field of mass spectrometry. As of 2007, the society had approximately 7000 members primarily from the US, but also from around the world. (ASMS). He received a Ph.D. in Chemistry from Institute of Chemistry, Chinese Academy of Sciences The Chinese Academy of Sciences (CAS) (Simplified Chinese: 中国科学院; Pinyin: Zhōngguó Kēxuéyuàn), formerly known as Academia Sinica in 1991, a M.S. from Chongqing University in 1988 and a B.S. from Sichuan Normal University Sichuan Normal University (SNU) (Chinese: 四川师范大学) is a university in Sichuan, China. Founded in 1938, the university has three campuses with a fourth under construction. External links
About Bridge Pharmaceuticals Bridge Pharmaceuticals is a US-headquartered company focused on providing cost effective, FDA compliant drug development services in Asia for US, EU and Asian based clients. Bridge is a spin off of SRI International (Menlo Park, CA). Bridge's Beijing preclinical laboratory is the first and only US level GLP and AAALAC designed facility in China. Bridge provides complete end-to-end drug development expertise and including US IND submissions. The Beijing facility provides services for FDA compliant GLP toxicology, pharmacology, predictive PK/ADMET, safety pharmacology, formulation and other services. Through its Vital Bridge joint venture, Bridge accesses animal supplies from the largest and only US-franchised quality animal breeding facilities in China. For more information, visit www.BridgePharmaceuticals.com or call (650) 859-4413. Copyright [c] 2006, Bridge Pharmaceuticals, Inc. All rights reserved. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion